07-0663-h7-MMAE

07-0663-h7 (monomethyl auristatin E) is an experimental antibody-drug conjugate (ADC) targeting Cadherin-17 (CDH17), a calcium-dependent cell adhesion protein predominantly expressed in the gastrointestinal tract and frequently overexpressed in colorectal, gastric, and pancreatic cancers. The ADC consists of the humanized monoclonal antibody 07-0663-h7, which was developed based on sequences disclosed in patent WO2023107558A1 by the University of California, Los Angeles (UCLA), conjugated to the potent microtubule-disrupting cytotoxin monomethyl auristatin E (MMAE). Upon binding to CDH17 on the surface of tumor cells, the ADC is internalized and trafficked to lysosomes, where the MMAE payload is released to inhibit tubulin polymerization, leading to G2/M phase cell cycle arrest and apoptosis. In preclinical research, this construct has been utilized to evaluate the efficacy of CDH17-targeted therapies in various gastrointestinal cancer xenograft models.